BLOG

Inner Workings: Lyme disease vaccines face familiar challenges, both societal and scientific

Just over 20 years ago, a Lyme disease vaccine called LYMErix was approved for sale in the United States. Researchers designed the vaccine to prevent the transmission of the tick-borne pathogen Borellia burgdorferi, which spurs a bacterial infection that can cause fever, headaches, and joint pain if left untreated.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}